Specialist market access professional who is highly skilled in cost-effectiveness analyses, PBS pricing negotiations, financial analyses and revenue calculators.

Adrian has more than nine years of experience in health economics and outcomes research across pharmaceuticals and medical devices. At HTANALYSTS, he specialises in market access and reimbursement strategy, including submission development, cost-effectiveness and cost-utility analyses, PBS pricing strategy and negotiations, financial modelling, and revenue calculator development. He has contributed to more than 40 PBAC, MSAC, ATAGI and Pharmac reimbursement submissions, including co-dependent technologies.

Adrian develops economic models to support reimbursement decisions in Australia and across Asia and Europe. His experience spans interventional medical devices, in-vitro diagnostics, vaccines, immunotherapy, targeted therapies, gene therapies and biosimilars. He has worked across therapeutic areas including oncology, cardiovascular disease, respiratory and infectious diseases, rare diseases, haematology and autoinflammatory conditions. In addition, he brings strong capability in real-world evidence and data analysis.

Adrian is currently a PhD candidate at UNSW and The George Institute for Global Health, where he focuses on health economics and health policy. He holds a Master of Health Technology Innovation from the University of Sydney and received the Dean’s Award for research in agent-based modelling. His work has been published in peer-reviewed journals and presented at national and international conferences.